Extended Data Fig. 10: AAV integration disrupts Ube3a-ATS via distinct mechanisms.
From: Cas9 gene therapy for Angelman syndrome traps Ube3a-ATS long non-coding RNA
a, AAV integration in the forward orientation gene traps Ube3a-ATS, causing premature transcription termination at the AAV vector-derived polyadenylation sequence element (red box). b, In the reverse orientation, convergent transcription with the AAV vector-derived Cas9 transcript disrupts Ube3a-ATS. c, Paternal Ube3a (red line) is similarly disrupted (“silenced”) by convergent transcription.
